Three-year follow-up from KEYNOTE-966 continues to support pembrolizumab added to gemcitabine and cisplatin in advanced biliary tract cancer, with durable overall survival benefit and no new safety concerns reported. The longer horizon data reinforce checkpoint blockade positioning for a population where durable outcomes remain challenging.